Understanding Checkpoint Inhibitors in NSCLC

Program Overview

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

Credit Expired

0.25 CE Credit(s)

Expires: June 24, 2022

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy

Activity Faculty

Ahmet Sezer, MD

Professor, Medical Oncology
Başkent University
Adana, Turkey

Sarah B. Goldberg, MD, MPH

Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT

Brian Henick, MD

Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY

Featured RMEI CE Activities

Climbing the Ladder to Optimal Outcomes in NTM-LD: Navigating a Clear Path from Diagnosis Thru Treatment

Halting the Vicious Vortex: Targeting Neutrophil Serine Protease Activation in Non-Cystic Fibrosis Bronchiectasis (NCFBE)

Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum®

Optimizing Biologic Therapy in Children with Moderate-to-Severe Atopic Dermatitis: A Care Team Forum®

Privacy | Terms of Use